Baseline bone health status in multi-ethnic South African postmenopausal breast cancer patients at initiation of aromatase inhibitor therapy : a descriptive study

dc.contributor.authorBaatjes, Karin J.en_ZA
dc.contributor.authorKotze, Maritha J.en_ZA
dc.contributor.authorMcCaul, Michaelen_ZA
dc.contributor.authorConradie, Magdaen_ZA
dc.date.accessioned2021-06-29T06:05:05Z
dc.date.available2021-06-29T06:05:05Z
dc.date.issued2019-04-02
dc.descriptionCITATION: Baatjes, K. J. et al. 2019. Baseline bone health status in multi-ethnic South African postmenopausal breast cancer patients at initiation of aromatase inhibitor therapy : a descriptive study. PLoS ONE, 14(4):e0214153, doi:10.1371/journal.pone.0214153.
dc.descriptionThe original publication is available at https://journals.plos.org/plosone
dc.description.abstractIntroduction: Osteoporosis (OP) risk factor assessment and bone mineral density (BMD) testing are frequently omitted at baseline in aromatase inhibitor (AI) studies, which may lead to misinterpretation of AI associated bone loss. The present study describes bone health of South African postmenopausal women of predominantly Mixed Ancestry, prior to AI treatment. Methods: This descriptive baseline study, nested in a prospective AI cohort study, included postmenopausal women with endocrine sensitive breast cancer, aged 50 to 80 years. A baseline questionnaire documented demographic-, medical-, lifestyle- and fracture history. Body weight was assessed clinically, and body composition and BMD measured via dual energy absorptiometry (DXA). Data was analysed in STATA 14 using descriptive and inferential statistics. Results: 101 participants were recruited, with a mean age of 61±7 years. Nearly a third (n = 32) of women at baseline fulfilled global criteria for bone protection (BMD T-score ≥-2SD (n = 18); BMD T-score -1.5SD to < -2SD with risk factors (n = 14). Lower body weight, body mass index (BMI), fat mass index and lean mass index were significantly associated with the participants with a BMD measurement in keeping with a diagnosis of OP (p <0.001). Low vitamin D was present in 93% of the cohort tested (n = 95), whilst deficient vitamin D status (<20ng/ml) was documented in 52 women (55%). Conclusions: In this study, a third of postmenopausal women considered for AI therapy fulfilled international criteria for bone protective pharmacological intervention. This emphasizes the need for clinical risk and BMD assessment in postmenopausal breast cancer patients at baseline. Body composition and bone health associations highlight bone fragility associated with lower body weight.en_ZA
dc.description.urihttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0214153
dc.description.versionPublisher's version
dc.format.extent14 pagesen_ZA
dc.identifier.citationBaatjes, K. J. et al. 2019. Baseline bone health status in multi-ethnic South African postmenopausal breast cancer patients at initiation of aromatase inhibitor therapy : a descriptive study. PLoS ONE, 14(4):e0214153, doi:10.1371/journal.pone.0214153.
dc.identifier.issn932-6203 (online)
dc.identifier.otherdoi:10.1371/journal.pone.0214153
dc.identifier.urihttp://hdl.handle.net/10019.1/110620
dc.language.isoen_ZAen_ZA
dc.publisherPLoSen_ZA
dc.rights.holderAuthors retain copyrighten_ZA
dc.subjectBone healthen_ZA
dc.subjectPostmenopausal osteoporosisen_ZA
dc.subjectAromatherapyen_ZA
dc.subjectBreast -- Canceren_ZA
dc.titleBaseline bone health status in multi-ethnic South African postmenopausal breast cancer patients at initiation of aromatase inhibitor therapy : a descriptive studyen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
baatjes_baseline_2019.pdf
Size:
540.96 KB
Format:
Adobe Portable Document Format
Description:
Download article
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: